DE60042283D1 - Kombination eines abl-, pdgf-rezeptor- und/oder kit rezeptor-tyrosin kinase inhibitors mit einer organischen substanz, die an alpha1-acidisches glycoprotein bindet - Google Patents

Kombination eines abl-, pdgf-rezeptor- und/oder kit rezeptor-tyrosin kinase inhibitors mit einer organischen substanz, die an alpha1-acidisches glycoprotein bindet

Info

Publication number
DE60042283D1
DE60042283D1 DE60042283T DE60042283T DE60042283D1 DE 60042283 D1 DE60042283 D1 DE 60042283D1 DE 60042283 T DE60042283 T DE 60042283T DE 60042283 T DE60042283 T DE 60042283T DE 60042283 D1 DE60042283 D1 DE 60042283D1
Authority
DE
Germany
Prior art keywords
abl
binds
alpha
combination
tyrosine kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042283T
Other languages
German (de)
English (en)
Inventor
Carlo Gambacorti-Passerini
Philipp Lecoutre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60042283D1 publication Critical patent/DE60042283D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60042283T 1999-12-27 2000-12-22 Kombination eines abl-, pdgf-rezeptor- und/oder kit rezeptor-tyrosin kinase inhibitors mit einer organischen substanz, die an alpha1-acidisches glycoprotein bindet Expired - Lifetime DE60042283D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI002711A ITMI992711A1 (it) 1999-12-27 1999-12-27 Composti organici
PCT/EP2000/013161 WO2001047507A2 (en) 1999-12-27 2000-12-22 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound

Publications (1)

Publication Number Publication Date
DE60042283D1 true DE60042283D1 (de) 2009-07-09

Family

ID=11384195

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042283T Expired - Lifetime DE60042283D1 (de) 1999-12-27 2000-12-22 Kombination eines abl-, pdgf-rezeptor- und/oder kit rezeptor-tyrosin kinase inhibitors mit einer organischen substanz, die an alpha1-acidisches glycoprotein bindet

Country Status (18)

Country Link
US (2) US20030125343A1 (enExample)
EP (1) EP1250140B1 (enExample)
JP (1) JP2003523325A (enExample)
CN (1) CN1304005C (enExample)
AR (1) AR030179A1 (enExample)
AT (1) ATE432069T1 (enExample)
AU (1) AU2171901A (enExample)
BR (1) BR0016817A (enExample)
CA (1) CA2394944A1 (enExample)
CO (1) CO5271710A1 (enExample)
DE (1) DE60042283D1 (enExample)
ES (1) ES2326307T3 (enExample)
HK (1) HK1050993A1 (enExample)
IT (1) ITMI992711A1 (enExample)
PE (1) PE20010991A1 (enExample)
PT (1) PT1250140E (enExample)
TW (1) TWI246917B (enExample)
WO (1) WO2001047507A2 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002223684A1 (en) * 2000-11-22 2002-06-03 Novartis Pharma Gmbh Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
EP1408978A4 (en) 2001-06-21 2005-07-13 Ariad Pharma Inc NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
NZ552335A (en) * 2001-10-25 2008-11-28 Novartis Ag Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
CA2479257A1 (en) * 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
AU2007201830C1 (en) * 2002-04-23 2017-09-07 Novartis Pharma Ag High drug load tablet
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20060052387A1 (en) * 2002-06-26 2006-03-09 Marsh Clay B Organic compounds
CA2498982A1 (en) * 2002-07-24 2004-01-29 Novartis Ag 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
AU2003250701A1 (en) * 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
CA2542007C (en) * 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
AU2003268185A1 (en) * 2003-08-25 2005-04-11 Dana-Farber Cancer Institute Inc. Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
DE602004030265D1 (de) * 2003-09-19 2011-01-05 Novartis Ag Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
PL1720853T3 (pl) † 2004-02-11 2016-06-30 Natco Pharma Ltd Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania
MXPA06015237A (es) 2004-06-29 2007-12-10 Amgen Inc Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
MX2007001399A (es) * 2004-08-02 2007-04-18 Osi Pharm Inc Compuestos que inhiben pirrolopirimidina multi-cinasa aril-amino sustituidas.
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US20060275365A1 (en) * 2005-06-07 2006-12-07 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20070059359A1 (en) * 2005-06-07 2007-03-15 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
DE602006015994D1 (de) * 2005-06-23 2010-09-16 Novartis Ag Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
WO2007076035A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
ATE541844T1 (de) * 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
EP2397138B1 (en) * 2006-04-20 2013-12-11 Janssen Pharmaceutica NV Aromatic amide derivatives as C-KIT kinase inhibitors
AU2007269540B2 (en) * 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
WO2008083491A1 (en) 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US20080248548A1 (en) * 2007-04-09 2008-10-09 Flynn Daniel L Modulation of protein functionalities
MX2010003200A (es) * 2007-09-25 2010-04-30 Teva Pharma Composiciones de imatibnib estables.
US8466151B2 (en) * 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
KR20100116607A (ko) 2008-01-11 2010-11-01 낫코 파마 리미티드 항암제로서의 신규한 피라졸로[3,4-ｄ]피리미딘 유도체
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2381777A4 (en) 2008-12-12 2012-08-08 Ariad Pharma Inc AZAINDOL DERIVATIVES AS KINASEHEMMER
ITRM20090578A1 (it) * 2009-11-10 2011-05-11 Noi Per Voi Onlus Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti.
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
TR201010618A2 (tr) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP4772247A2 (en) 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
WO2020152629A1 (en) 2019-01-23 2020-07-30 Novartis Ag New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US20030069174A1 (en) * 1997-03-10 2003-04-10 Ludwig Pichler Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
AU6014900A (en) * 1999-07-13 2001-01-30 Kyowa Hakko Kogyo Co. Ltd. Staurosporin derivatives
OA12118A (en) * 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.

Also Published As

Publication number Publication date
ATE432069T1 (de) 2009-06-15
US20090221519A1 (en) 2009-09-03
WO2001047507A3 (en) 2002-04-04
PE20010991A1 (es) 2001-10-23
CA2394944A1 (en) 2001-07-05
EP1250140A2 (en) 2002-10-23
CN1414858A (zh) 2003-04-30
US20030125343A1 (en) 2003-07-03
JP2003523325A (ja) 2003-08-05
AU2171901A (en) 2001-07-09
ITMI992711A1 (it) 2001-06-27
ES2326307T3 (es) 2009-10-07
ITMI992711A0 (it) 1999-12-27
EP1250140B1 (en) 2009-05-27
AR030179A1 (es) 2003-08-13
CO5271710A1 (es) 2003-04-30
HK1050993A1 (zh) 2003-07-18
CN1304005C (zh) 2007-03-14
WO2001047507A2 (en) 2001-07-05
PT1250140E (pt) 2009-08-24
BR0016817A (pt) 2002-10-01
TWI246917B (en) 2006-01-11

Similar Documents

Publication Publication Date Title
ATE432069T1 (de) Kombination eines abl-, pdgf-rezeptor- und/oder kit rezeptor-tyrosin kinase inhibitors mit einer organischen substanz, die an alpha1-acidisches glycoprotein bindet
NO20000487D0 (no) Substituerte quinazolinderivater og anvendelse derav som tyrosin kinase inhibitorer
NO20021820L (no) Tyrosinkinaseinhibitorer
EP1161433A4 (en) TYROSINE KINASE INHIBITORS
NO20023713D0 (no) 2-benzotiazolyl-urea-derivater samt anvendelse derav som proteinkinaseinhibitorer
ATE318603T1 (de) Pyrrolotriazin kinasehemmer
NO20014970L (no) Cyklisk protein-tyrosin-kinase-inhibitor
NO20011575D0 (no) Substituerte 3-cyanokinoliner som proteintyrosin-kinase- inhibitorer
NO20011574D0 (no) Substituerte 3-cyanokinoliner som proteintyrosin-kinsase- inhibitorer
DZ3186A1 (fr) Ptéridinones utilisées comme inhibiteurs de kinase.
NL300242I2 (nl) Omega-carboxyaryl gesubstitueerde difenylureums als raf kinaseremmers.
ATE395346T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
EE200200715A (et) Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
ATE430149T1 (de) Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
CY2012026I1 (el) Παραγωγα κουιναζολινης ως αναστολεις vegf
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
EA200400029A1 (ru) КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА АЛЬДОСТЕРОНА И ИНГИБИТОРА ГМГ-КоА-РЕДУКТАЗЫ
EP1534268A4 (en) TYROSINE KINASE INHIBITORS
DE60101323D1 (de) Tricyclische proteinkinasehemmer
NO20015062L (no) Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
EP1496897A4 (en) Tyrosine kinase inhibitor
ATE387451T1 (de) Chinazolinderivate als src- tyrosinkinaseinhibitoren
ITBO990293A0 (it) Metodo di controllo di banconote .
ITTO20020202A1 (it) Distributore automatico di pizze calde ed affini e relativo metodo difunzionamento.
ITRM20010070A0 (it) Procedimento di evoluzione controllata di vini e relativo dispositivodi attuazione.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN